Cipla US

Cipla US Market Maintains Stability Amid Regulatory Shifts

How Is Cipla US Segment Navigating Trump’s Executive Order? Cipla US business, contributing $221 million in Q4 FY25, remained flat due to Lanreotide supply issues and delayed launches, as reported on May 14, 2025. Despite Trump’s executive order on drug pricing, Cipla expects minimal impact, as US generic prices are already competitive globally. FY26 projections…

Read More